Please, while it is understandable to want to talk about it, especially for our Eastern European members, LF is not the place to discuss this.
Shane D.
Administrator
- Male
- from Pensacola Beach, Fl.
- Member since Jan 26th 2015
- Last Activity:
Posts by Shane D.
-
-
Solid state fusion, as a term for cold fusion, dates back decades.
Team Google in attendance it seems they have not abandoned the field. Neither has Matt Trevithick in my opinion.
Will future conferences have a Solid State Energy Summit? How was this one decided upon? Is it an ICCF creation or other?
Whatever is going on with the former TG, IMO having this ICCF in Silicon Valley is a milestone, and a very promising development. Something Page probably had in mind when going through the trouble to make this happen. And something we should keep in mind as the conference approaches.
I did a little search on LENR-CANR and it appears this is the first ICCF in the innovation capital of the world. It will attract some attention from the right people. An added bonus is that SV is also an area rich with investors looking for their next green venture.
-
The race is on... My hope is the Solid State Energy Summit will bring news that answers that question. I expect you have a rough timeline and as that gets clearer you will have a solid date for market entry. I look forward to your announcement...
Thanks Big Thanks
LF staff, and MTI are working on that. Stay tuned.
-
But believe me India will be one of the first state that will sue and jail the responsible for this top down FM/R//B genocide.
They already sued WHO: Indian Bar Association sues WHO scientist over Ivermectin | Columnists | thedesertreview.com
-
By teh end of the century Amsterdam will be under water. No need to be climate town....
LENR is going to save us.
-
Very high quality, and informative production. Congratulations to the LF team of David, Alan S, Ruby for making it happen, and forum member Jeff for volunteering his editing skills. Many thanks go to the distinguished members of the panel for contributing their time, and expertise, and special thanks go to Gordon and Whitehouse for their invention, and commitment to open science.
This is the kind of team effort that will help keep the LENR community interconnected between conferences and shorten the innovation process from concept to lab, to market. We anticipate many more to come.
-
European MEPs Call for Immediate Ouster of European Commission President Due to Conflicts of Interest with Pfizer & Mass COVID-19 Vaccination Program
This new video shows the degree to which private pharma and US public health agencies have fused into one:
-
No smart people here
Just really bad science
A sign posted at ICCF24
Or at the
Solid State Energy Summit
Thanks Team Google
When I first read that, I hoped he did not mean it to sound so condescending. In interviews, sometimes you say things you wished you could take back.
-
PLOP
US20210151206A1
THE INVINCIBLE TEAM
Thanks as always. That one patent application resulting from the TG funded effort, IMO, had the best chance to slip by the USPTO examiner and be approved. It was the only solid lead reported in the Nature paper that I recall.
Sadly it was rejected. And in no unambiguous terms, as the examiner used quite strong wording IMO in his very long rebuttal. He even went so far as to call LENR (which the team denied it being) "fringe science", and gasp, used Schenkel's own public writings against him. What a low blow.
Nothing new here, LENR has seen this all before. As always it appears that whoever wants to capitalize/monetize on their lab results, or theory, will just have to make something with it, and go from there.
-
Matt’s DCVC bio. It seems he’ll be focused on clean energy investments. It will be interesting to see what details filter out over time. Perhaps there’ll be some LENR in there, but who knows. It’s only a guess, but it feels more and more likely that Google’s interest in LENR is over.
Nice how they don't shy away from mentioning CF in his bio. Maybe one day the name will come back in vogue:
"Matt also directed a reevaluation of cold fusion that included sponsored research at MIT and facilitated Alphabet’s investment in Commonwealth Fusion Systems"
-
Team Google patent inventor
Ross Koningstein
Overview
Number of Portfolio Companies - 1
CB Rank (Investor) 118,976
Investor Type
Individual/Angel
- Ross Koningstein received an undergraduate degree in EE/CS at Carleton University in Ottawa, and went on to get a Ph.D. in aerospace robotics at Stanford University.
- Ross was the co-founder of SpeedQuest (a product that made PC’s faster). He provided software consulting that developed flight simulation software for the hit game “Chuck Yeager’s Advanced Flight Trainer.” He was also co-founder and vice president at CriSys Limited, a provider of a fault-tolerant map-based 9-1-1 dispatch systems. Ross was the VP of Engineering at two dot-com era startups: On Your Mind, and Bluedog Inc.
- Ross was Google’s first director of engineering. He is one of the inventors of Google’s CPC AdWords product, has automated and streamlined Google’s ad sales organization, helped with the design and build of Google’s breakthrough data center in The Dalles, Oregon, and is currently an engineer on Google’s RE<C effoJacob's.
Information above
is from CrunchBase
The following is an interview by Jason Jacobs.
Episode recorded
September 28th. 2021
Episode 180: Ross Koningstein, Director Emeritus at Google
https://www.myclimatejourney.co/episodes/ross-koningstein
Source
myclimatejourney.co was first indexed by Google in April 2019- ·https://www.myclimatejourney.co/episodes/ross-koningstein
- ·Your connection to this site is secure
gbgoblenote just found this interview by Jason Jacobs and am posting a little bit of it here for discussion. Reading the whole interview is recommended. Excellent... I look forward to learning more and wish Team Google et. al. the best of luck... -end gbgoblenote
Ross Koningstein
So we worked with some groups in Washington DC, NGOs who were putting together a campaign to increase the ability of federal policy to support innovation in various types of nuclear technologies. And you know, those folks have been quite successful.
And lastly, at the time there was an interest in things going on in cold fusion. Now, I'm not like a cold fusion believer, but I do know in the scientific area, if you completely shut off an area of science to any investigation, then that withers and it, you know, you can destroy people's careers.
So the stuff that we saw in cold fusion was really bad science as opposed to bad topic area. And so we wanted to see if you had a bunch of really smart scientists say, what would they look for in that area in which cold fusion was reputed to be? And we funded them for a couple of years to actually examine those set of conditions, which turned out to be really, really difficult to create and sometimes observe.
Jason Jacobs: And what was the motivation from Google at the time of supporting these efforts? Was it purely for the collective good or was there any self interest involved and if so, what did that look like?
Ross Koningstein: I think in any situation where you have people making decisions, they're gonna be doing it both because they have a long term view that there might be something good that comes out of it for society, and often it's because there is a personal interest component.
And like I was saying at the intersection of why different companies do what, in our case, the plasma fusion partnership was a very clear fit for why Google could move that needle forward. And so once we had landed in that topic area, that one seemed like a really positive way to move forward. So I think, to answer your question, it's a bit of both and I'm sure it varies all over the place.
Nice find Gregory Byron Goble . Koningstein also said this in the interview:
"I help through our group sponsor research, for example, at a couple of universities in Nuclear Excitation via Electron Capture, which is a recently observed form of nuclear transition that might have an energy option. So that could be really cool for, let's call it, designer nuclear power for portable applications."
-
Thanks. I had not seen this before. I did not know they nicknamed themselves "Team Cold Fusion". Interesting choice considering the field has tried so hard to rename it LENR, because of the stigma associated with CF.
-
Some background: "A longtime professor of physics at UCLA, Wong served as the director of the Plasma Physics Laboratory at UCLA"
That is from a US DOJ press release: https://tinyurl.com/2p98e8se
headlined "Former UCLA Physics Professor Agrees To Plead Guilty In Federal Contract Fraud Case And Pay Nearly $1.7 Million In Damages"
He should have taken a lesson from Rossi on how to fake invoices.
-
One funding source for that Diablo Canyon study recommending it stay open, was a member of Team Google.
-
Linear Ion Dynamics
Shane D. Has Wong et al been discussed here?
Worthy of a new thread under Players I think... not sure though.
Please let me know. If not discussed I'll work up an intro and start one... or fold old info into this news.
Certainly
Big Thanks
That is the Alpha Ring International guy and there have been some posts about them scattered about. Nothing all in one place that I can see though. If you dig and find something worthy about him, then of course a dedicated thread would be in order.
-
Coincidentally my brother is an oncologist who took care of the one of the brothers who were commercializing the Papp engine. I had a lot of time to talk with them during that time. They are a couple of engineers, one brother mechanical and one electrical that did control systems (he was the one who had cancer). They showed me photos and videos of what they were doing. They were the original partners of Joseph Papp. They ran a small machine shop in Iowa. I think one of the brothers tried to steal the concept and built a company and then finally ended up under criminal investigation. The other brother contacted me one to ask me if I could help him get some thorium. Haven't heard from them since.
Yes, that was a colorful story. What I remember most though, is that Papp took his secrets to the grave. That is the moral of the story IMO. Not what he claimed his machine could do. Many in this field have done, and will continue to do, the same.
Ironically, the many selfless researchers who have kept no secrets, seem to suffer the same fate.
-
... and indeed I put foregoing brochure in playground place, following the save rule of relegate irrelevant or lunatic opinions behind nominal fences. Enclosure appears lately a bit too crowded.
That is fine. This is a good place to keep until we find out more. The only reason I find it interesting is because of Hagelstein and Nagel. Good find nonetheless. Anything LENR we need to check it out. Thanks.
Just in case there is something to this, I moved it to this thread. It may get lost in the Playground.
-
"This energy gain phenomenon may best be theoretically explainable by the same or similar process
as observed in low energy nuclear reactions (LENR)."
The only thing I can find on WPPEnergy GmbH is this video with COO Troy MacDonald from July 2021. In it he mentions the green H tech, and at 6:02 LENR. The rest is greek to me (hard to understand); i,e, Blockchain, NFT's, and Crpyto.
WPP Energy GmbH, Troy E. MacDonald, COO & CIO – It's Market
Since Nagel and Hagelstein are listed as being on the "Team", I am curious. Have we talked about them before? The forum search gives me error code. .
-
Mexican Institute of Social Security Large Observational Study: Home Treatment Kit with Ivermectin Reduces Hospitalizations & Death
https://trialsitenews.com/mexi…s-hospitalizations-death/
This large retrospective observational population study out of Mexico is a testament to the benefits of treating mild outpatient Covid-19 cases with a medical kit at home. They found that the incidence of hospitalization was only 6.14% in patients who received a kit and 11.71% in those who did not. In the multivariate model, receiving a medical kit was associated with a lower risk of hospitalization or death from COVID-19: adjusted risk ratio 0.35 (95% confidence interval 0.30–0.40).
Background
This retrospective, two-group comparative study was sponsored by the Mexican Institute of Social Security (Instituto Mexicano del Seguro Social, (IMSS), a system providing healthcare to about 68 million people or 54% of the Mexican population. Operating approximately 1,400 primary care medical units, 270 general community hospitals, and 25 tertiary and quaternary care medical centers distributed throughout the 32 Mexican states.
During the pandemic, IMSS implemented respiratory care modules in a bid to classify and care for COVID-19 patients. For the cohort of patients with mild COVID-19 without respiratory symptoms, a large study was set up comparing a group that received the treatment kit with those that did not.
The treatment kits included an information brochure, face masks, a pulse oximeter, a three-day course of azithromycin (500 mg on day 1, 250 mg on days 2 and 3), a two-day course of ivermectin 6 mg daily, and several acetaminophen and aspirin tablets. The ivermectin and aspirin are likely to be what provided the benefits. The ivermectin dosing was much too low, but still probably helped. The aspirin would help prevent the microthrombosis that is so prevalent in Covid-19. Many believe microthrombosis is the main driver of severe disease in Covid-19. There is also evidence that platelet agglutination is the initial stage of the thrombosis in Covid-19.
The study team included a total of 28,048 laboratory-confirmed SARS-CoV-2 patients: 7,898 (28.2%) received a medical kit and 20,150 (71.8%) did not. The incidence rates of hospitalization and death combined were calculated.
The Study Methods
This study was designed to investigate the hospitalization and mortality rates of a large sample of adults who received the primary treatment kit in comparison with an equally large cohort of patients who declined the kit yet continued monitoring via telehealth.
A retrospective, two-group comparative study was conducted with secondary data via the National Family Medicine Information System of the IMSS. This database contains the personal and clinical records of every patient, including their diagnosis and prescribed medications. All data is captured in real-time by the family physician while attending to the patient.
A second database was set up by the epidemiological surveillance system at the IMSS covering the period of February 1-May 16, 2021. The data corresponded to ambulatory patients aged 18 years and older and over with confirmed COVID-19 diagnosis and with information about the treatment kit delivery only. Records from the second epidemic wave from January 1–August 30, 2021, were analyzed. The study team included data regarding sex, age, medical conditions (e.g., obesity, hypertension, diabetes, cardiovascular disease), follow-up by telephone, and whether they agreed to use the treatment kit was obtained for each patient, as well emergency room visits and hospitalization. Information regarding death was obtained and verified using the hospital and mortality registries.
Results
The study authors, led by Cesar Raul Gonzalez-Bonilla, Evidence Analysis and Synthesis Research Unit, Health Research Coordination, Education and Research Unit, Medical Benefits Directorate, Mexican Institute of Social Security, report that those mild COVID-19 patients receiving the home treatment kit had a hospitalization rate of 6.14% as compared to the cohort not receiving the home treatment kit at 11.71%.
As is the case in other parts of North America, the authors report that comorbidities (e.g., obesity, diabetes, etc.) are associated with an increased risk of hospitalization or death. But those rates were reduced in the cohort that received early treatment or telephone follow-up.
Multivariate analysis revealed that the home-based mild COVID-19 patients receiving the home treatment kits were associated with a lower risk of hospitalization and death from COVID-19 with an adjusted risk ratio of 0.35 (95% confidence interval 0.30–0.40).
Summary
The authors conclude that a multimodal strategy of the type employed in Mexico could possibly reduce the risk of hospitalization and death in adult outpatients with mild COVID-19. Based on a review of dozens of randomized controlled trials, observational studies, and countless physician interviews, the study results here indicate that even a marginally efficacious inexpensive regimen can save lives, even when administered early. TrialSite goes on record that sending patients home with no treatment and only instructions to go to the emergency department if/when they become hypoxic was cruel and immoral. It also directly caused the deaths of hundreds of thousands of Americans.
Lead Research/Investigator
Cesar Raul Gonzalez-Bonilla, Ph.D. Evidence Analysis and Synthesis Research Unit, Health Research Coordination, Education and Research Unit, Medical Benefits Directorate, Mexican Institute of Social Security.
Call to Action: Published as preprint/pre-proof the article is available in the journal Archives of Medical Research.
A Multimodal Strategy to Reduce the Risk of Hospitalization/death in Ambulatory Patients with COVID-19
SocArxiv, pressured by the cancel culture mob over this Mexico City Ivermectin paper, caves and withdraws it. "This is the first time we have used our prerogative as service administrators to withdraw a paper from SocArXiv".
ivermectin – SocOpen: Home of SocArXivsocopen.orgPreamble by Philip N. Cohen, director of SocArXiv
SocArXiv’s steering committee has decided to withdraw the paper, “Ivermectin and the odds of hospitalization due to COVID-19: evidence from a quasi-experimental analysis based on a public intervention in Mexico City,” by Jose Merino, Victor Hugo Borja, Oliva Lopez, José Alfredo Ochoa, Eduardo Clark, Lila Petersen, and Saul Caballero. [10.31235/osf.io/r93g4]
The paper is a report on a program in Mexico City that gave people medical kits when they tested positive for COVID-19, containing, among other things, ivermectin tablets. The conclusion of the paper is, “The study supports ivermectin-based interventions to assuage the effects of the COVID-19 pandemic on the health system.”
The lead author of the paper, José Merino, head of the Digital Agency for Public Innovation (DAPI), a government agency in Mexico City, tweeted about the paper: “Es una GRAN noticia poder validar una política pública que permitió reducir impactos en salud por covid19” (translation: It is GREAT news to be able to validate a public policy that allowed reducing health impacts from covid19). The other authors are officials at the Mexican Social Security Institute and the Mexico City Ministry of Health, and employees at the DAPI.
We have written about this paper previously. We wrote, in part:
“Depending on which critique you prefer, the paper is either very poor quality or else deliberately false and misleading. PolitiFact debunked it here, partly based on this factcheck in Portuguese. We do not believe it provides reliable or useful information, and we are disappointed that it has been very popular (downloaded almost 10,000 times so far). … We do not have a policy to remove papers like this from our service, which meet submission criteria when we post them but turn out to be harmful. However, we could develop one, such as a petition process or some other review trigger. This is an open discussion.”
The paper has now been downloaded more than 11,000 times, among our most-read papers of the past year. Since we posted that statement, the paper has received more attention. In particular, an article in Animal Politico in Mexico reported that the government of Mexico City has spent hundreds of thousands of dollars on ivermectin, which it still distributes (as of January 2022) to people who test positive for COVID-19. In response, University of California-San Diego sociology professor Juan Pablo Pardo-Guerra posted an appeal to SocArXiv asking us to remove the “deeply problematic and unethical” paper and ban its authors from our platform. The appeal, in a widely shared Twitter thread, argued that the authors, through their agency dispensing the medication, unethically recruited experimental subjects, apparently without informed consent, and thus the study is an unethical study; they did not declare a conflict of interest, although they are employees of agencies that carried out the policy. The thread was shared or liked by thousands of people. The article and response to the article prompted us to revisit this paper. On February 1, I promised to bring the issue to our Steering Committee for further discussion.
I am not a medical researcher, although I am a social scientist reasonably well-versed in public health research. I won’t provide a scholarly review of research on ivermectin. However, it is clear from the record of authoritative statements by global and national public health agencies that, at present, ivermectin should not be used as a treatment or preventative for COVID-19 outside of carefully controlled clinical studies, which this clearly was not. These are some of those statements, reflecting current guidance as of 3 February 2022.
- World Health Organization: “We recommend not to use ivermectin, except in the context of a clinical trial.”
- US Centers for Disease Control and Prevention: “ivermectin has not been proven as a way to prevent or treat COVID-19.”
- US National Institutes of Health: “There is insufficient evidence for the COVID-19 Treatment Guidelines Panel (the Panel) to recommend either for or against the use of ivermectin for the treatment of COVID-19.”
- European Medicines Agency: “use of ivermectin for prevention or treatment of COVID-19 cannot currently be recommended outside controlled clinical trials.”
- US Food and Drug Administration: “The FDA has not authorized or approved ivermectin for use in preventing or treating COVID-19 in humans or animals. … Currently available data do not show ivermectin is effective against COVID-19.”
For reference, the scientific flaws in the paper are enumerated at the links above from PolitiFact, partly based on this factcheck from Estado in Portuguese, which included expert consultation. I also found this thread from Omar Yaxmehen Bello-Chavolla useful.
In light of this review, a program to publicly distribute ivermectin to people infected with COVID-19, outside of a controlled study, seems unethical. The paper is part of such a program, and currently serves as part of its justification.
To summarize, there remains insufficient evidence that ivermectin is effective in treating COVID-19; the study is of minimal scientific value at best; the paper is part of an unethical program by the government of Mexico City to dispense hundreds of thousands of doses of an inappropriate medication to people who were sick with COVID-19, which possibly continues to the present; the authors of the paper have promoted it as evidence that their medical intervention is effective. This review is intended to help the SocArXiv Steering Committee reach a decision on the request to remove the paper (we set aside the question of banning the authors from future submissions, which is reserved for people who repeatedly violate our rules). The statement below followed from this review.
SocArXiv Steering Committee statement on withdrawing the paper by Merino et al. (10.31235/osf.io/r93g4).
This is the first time we have used our prerogative as service administrators to withdraw a paper from SocArXiv. Although we reject many papers, according to our moderation policy, we don’t have a policy for unilaterally withdrawing papers after they have been posted. We don’t want to make policy around a single case, but we do want to respond to this situation.
We are withdrawing the paper, and replacing it with a “tombstone” that includes the paper’s metadata. We are doing this to prevent the paper from causing additional harm, and taking this incident as an impetus to develop a more comprehensive policy for future situations. The metadata will serve as a reference for people who follow citations to the paper to our site.
Our grounds for this decision are several:
- The paper is spreading misinformation, promoting an unproved medical treatment in the midst of a global pandemic.
- The paper is part of, and justification for, a government program that unethically dispenses (or did dispense) unproven medication apparently without proper consent or appropriate ethical protections according to the standards of human subjects research.
- The paper is medical research – purporting to study the effects of a medication on a disease outcome – and is not properly within the subject scope of SocArXiv.
- The authors did not properly disclose their conflicts of interest.
We appreciate that of the thousands of papers we have accepted and now host on our platform, there may be others that have serious flaws as well.
We are taking this unprecedented action because this particular bad paper appears to be more important, and therefore potentially more harmful, than other flawed work. In administering SocArXiv, we generally err on the side of inclusivity, and do not provide peer review or substantive vetting of the papers we host. Taking such an approach suits us philosophically, and also practically, since we don’t have staff to review every paper fully. But this approach comes with the responsibility to respond when something truly harmful gets through. In light of demonstrable harms like those associated with this paper, and in response to a community groundswell beseeching us to act, we are withdrawing this paper.
We reiterate that our moderation process does not involve peer review, or substantive evaluation, of the research papers that we host. Our moderation policy confirms only that papers are (1) scholarly, (2) in research areas that we support, (3) are plausibly categorized, (4) are correctly attributed, (5) are in languages that we moderate, and (6) are in text-searchable formats. Posting a paper on SocArXiv is not in itself an indication of good quality – but it is often a sign that researchers are acting in good faith and practicing open scholarship for the public good. We urge readers to consider this incident in the context of the greater good that open science and preprints in general, and our service in particular, do for researchers and the communities they serve.
-
All elderly people should be banned as well to restaurants as many of those have a a weak immune system and even if they took the vaccine, they would not be protected from getting covid. So in order to go to an event you should show a covid pass and a birth certificate. This way we young and healthy would avoid getting covid and then not pass it on the elderly in secondary infections.
Good idea. We can also isolate all the young people with "a body from hell" so they don't pollute the healthy.